Two Paul Hastings partners join King & Spalding

King & Spalding has boosted its IP practice with two new partners in its trial and global disputes practice group in New York.

Gerald Flattmann and Evan Diamond, who both join from Paul Hastings, have experience with biotechnology and pharmaceutical patent litigation.

Flattmann will also serve as the firm’s global chair of life sciences patent litigation. He focuses his practice on all aspects of patent litigation, licensing and counselling.

Diamond also focuses on patent litigation matters and has led a number of trial teams that have obtained favourable judgments and settlements for branded pharmaceutical clients in Hatch-Waxman litigation and inter partes review proceedings.

Andy Bayman, head of King & Spalding’s trial and global disputes practice group, said: “Their capabilities in the pharma space dovetail well with the firm’s focus on clients in the life sciences sector, and they add to the firm’s deep trial bench.”

Flattmann said that he and Diamond look forward to working with new colleagues to help clients “develop strong patent strategies so they can navigate the challenges and complexities that arise from litigation".

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.